Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results
09. August 2022 07:00 ET
|
Avadel Pharmaceuticals plc
Received tentative approval for LUMRYZ™ (sodium oxybate) extended-release for oral suspension from FDA on July 18Advancing key activities to potentially accelerate final approval and shorten launch...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
02. August 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspension
19. Juli 2022 07:00 ET
|
Avadel Pharmaceuticals plc
- Validates the safety profile and clinical efficacy of LUMRYZ - Pursuing strategies to accelerate final approval DUBLIN, Ireland, July 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc...
Avadel Pharmaceuticals Provides Corporate Update
29. Juni 2022 16:05 ET
|
Avadel Pharmaceuticals plc
Pursuing strategies to accelerate final approval of FT218 NDAOptimizing cost structure to fund strategic priorities and extend cash runwayContinuing key activities to accelerate launch timing of...
Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2022 Young Investigators Research Forum
03. Juni 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 03, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
02. Juni 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel to Present Clinical Data for FT218 at SLEEP 2022
19. Mai 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, May 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the...
Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
18. Mai 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
09. Mai 2022 07:00 ET
|
Avadel Pharmaceuticals plc
FDA review of NDA for FT218 continues; launch readiness preparations on-track to support potential commercial launch Presented interim results from ongoing RESTORE open-label extension / switch...
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter Financial Results on May 9
02. Mai 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, May 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it...